Inventiva (NASDAQ:IVA) Receives “Buy” Rating from HC Wainwright

Inventiva (NASDAQ:IVA)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $13.00 target price on the stock. HC Wainwright’s target price points to a potential upside of 342.18% from the company’s previous close.

Separately, TD Cowen assumed coverage on shares of Inventiva in a report on Friday, February 21st. They issued a “buy” rating and a $10.00 price objective for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Inventiva has a consensus rating of “Moderate Buy” and a consensus price target of $12.60.

Inventiva Stock Up 2.1 %

NASDAQ:IVA opened at $2.94 on Friday. The company has a 50-day moving average price of $2.69 and a 200-day moving average price of $2.48. Inventiva has a 12 month low of $1.53 and a 12 month high of $3.98.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.